Global Market Access Director - Gene Therapy & Value

BioSpace; Boston (MA); On-site; USD 182,000 - 266,000; Full time

Benefits offered by this job

Company bonus program

Medical, dental, vision benefits

Retirement/pension plans

Vacation and flexible time off

Job summary

Lilly is seeking a Senior Director, Market Access to lead global pricing, access, and contracting across gene therapy assets. You will shape the strategy with LV&A and IVA, setting the frame for payer engagement worldwide and ensuring coherence across markets.

You will build new payment models, craft the value narrative for HTA dossiers, and coordinate with policy partners to influence markets from the US to Europe. Travel is estimated 10–20%.

Qualifications

• Bachelor's degree in a relevant field
• 10+ years of progressive market access, pricing, or payer strategy experience in biopharma with global/multi-country scope
• Working knowledge of payer, HTA, and reimbursement systems in major international markets (US, China, France, Germany, Japan, UK)
• Experience building pricing, access, or contracting frameworks from scratch

Responsibilities

• Own the global market access strategy for gene therapy assets across LV&A and IVA
• Lead development of durability-linked and outcomes-based contracting playbooks
• Translate evidence into value narratives to support global value dossiers and local HTA submissions
• Represent LRM in external policy discussions and payer negotiations
• Drive cross-asset pricing/contracting coherence and collaboration with Lilly teams

Skills

Global strategy

Pricing & access

Payer engagement

Policy & government affairs

Contracting frameworks

Education

Bachelor's degree

Job description

Lilly is seeking a Senior Director, Market Access to lead global pricing, access, and contracting across gene therapy assets. You will shape the strategy with LV&A and IVA, setting the frame for payer engagement worldwide and ensuring coherence across markets.

You will build new payment models, craft the value narrative for HTA dossiers, and coordinate with policy partners to influence markets from the US to Europe. Travel is estimated 10–20%.